secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001213900-23-095155
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt to acquire Evofem in stock merger; assumes ~$100M debt, targets women's health market
--------------------------------------------------------------------------------

- Evofem shareholders to receive 610K shares of Aditxt common and 2,327 shares of Series A-1 preferred.
- Aditxt assumes ~$100M senior indebtedness; issues $5M Jan 2024 secured notes, $8M Sep 2024 secured notes, $5M unsecured notes.
- Evofem's Phexxi net sales $13.4M for first 9 months 2023; non-hormonal contraceptive market projected $27.7B to $52.2B by 2031.
- Closing requires shareholder approvals, SEC S-4 effectiveness, Nasdaq compliance, and warrant/note holder agreements.
- Aditxt must provide $3M loan to Evofem by Jan 31, 2024; deal may be terminated if not closed by May 8, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390023095155/0001213900-23-095155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390023095155/ea189850-8k425_aditxtinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-095155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer